Easom Eric's Form 4 filing
AN2 Therapeutics, Inc. (ANTX) · filed Nov 9, 2022
- Accession no.
- 0000899243-22-035472
- Filed
- Nov 9, 2022
- Trade date
- Nov 8-9, 2022
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market sales total $267.8K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Easom EricCIK 0001914503 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 8, 2022 | Common Stock | SSaleDisposed | −5,800 | $15.41 | −$89,378 | 16,273 | Direct | |
| Nov 8, 2022 | Common Stock | SSaleDisposed | −1,255 | $16.38 | −$20,556.9 | 15,018 | Direct | |
| Nov 9, 2022 | Common Stock | SSaleDisposed | −10,111 | $15.61 | −$157,832.71 | 4,907 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.